The report, in context
What this development means—and what it does not.
The FDA approved Belotero Intense (+) Lidocaine on July 9, 2026 for submucosal and/or subcutaneous implantation for lip augmentation in adults over 21. Approval confirms an authorized indication and labeling pathway, not that one filler is best for every lip shape, anatomy or risk profile.
Related Dagan MD pathways
Continue with the relevant clinical context.
Inclusion is not an endorsement; treatment suitability, product safety and postoperative care require individualized guidance from a qualified clinician.